Medical devices, healthcare technology and the business of care
510(k) clearance · K261837

FINDER Flu A&B/SARS-CoV-2 Test

Baebies, Inc. · Decision date Sep 11, 2026

MEDTECHLEDGER EXPLANATIONK261837

What did the FDA decide?

FDA recorded a substantially equivalent (SESE) decision for K261837 on September 11, 2026, clearing the FINDER Flu A&B/SARS-CoV-2 Test from Baebies, Inc. of Durham, North Carolina. The submission was received June 2, 2026, and reviewed under 21 CFR 866.3981, Class II, product code QOF, in the Microbiology panel. The test is an automated, multiplexed, real-time RT-PCR assay run on the FINDER Instrument for qualitative detection and differentiation of SARS-CoV-2, influenza A and influenza B nucleic acid in nasopharyngeal swab specimens from individuals with signs and symptoms of respiratory tract infection.

The cleared change is the instrument user interface: the subject device is FINDER Instrument model 100-000082 with an integrated touchscreen, compared with model 100-000054 with a tablet interface in predicate K252269. The applicant states the underlying technology, performance and risk are unchanged and that the interface change was verified and validated. The decision summary lists no calibration requirement and describes an internal control targeting human RPP30 plus separately sold external controls. Analytical and clinical performance data are not reproduced in the supplied excerpts, so the basis for the equivalence finding beyond the interface change remains unverified here.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Microbiology
Decision date
Sep 11, 2026

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
K261837
Regulatory pathway
510(k) premarket notification
Applicant
Baebies, Inc.
Product code
QOF
Decision code
SESE
Decision date
Sep 11, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Multi-Target Respiratory Specimen Nucleic Acid Test Including Sars-Cov-2 And Other Microbial Agents.

Applicant
Baebies, Inc.
Product code
QOF
FDA device class
2

FDA decision timeline

  1. K261837 received

    Application receipt date recorded by FDA.

  2. K261837 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

Other records with product code QOF

Product / regulatory recordCompanyPathwayDecision dateSource
GenMark Diagnostics, Inc.510(k) clearanceOct 30, 2026FDA
Cepheid510(k) clearanceOct 22, 2026FDA
Cepheid510(k) clearanceOct 2, 2026FDA
Cepheid510(k) clearanceSep 25, 2026FDA
Biofire Diagnostics510(k) clearanceSep 22, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Baebies, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Durham, NC

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records